AAIC Day 3: Dispatch from the World’s Largest Alzheimer’s Research Conference
The Being Patient team is on the ground at the Alzheimer's Association International Conference 2025 in Toronto, and here's one of the topics the conference center is abuzz about: blood biomarker tests.
On Day Two of the Alzheimer’s Association International Conference (AAIC) 2025, one theme continues to rise to the surface: blood-based biomarkers.
Reporting from the floor of the conference, Being Patient founder and editor-in-chief Deborah Kan noted the momentum and buzz surrounding these promising diagnostic tools. While blood tests for Alzheimer’s are not yet used as standalone diagnostic methods, they’re already playing a critical role in the early detection process.
“The issue is that there’s so many different biomarkers that are coming to market, being studied, getting the data, that healthcare professionals who are using them seem confused as to which ones are the most accurate,” Kan said. “Now we’re going to see a lot of changes in diagnostic aided by the blood test.”
With a growing list of biomarkers under study and in use, healthcare professionals are facing uncertainty around which tests are most reliable and how to interpret the results in clinical settings. Meanwhile, new guidelines shared this week at AAIC indicate these tests could in some cases replace more standard diagnostics like spinal taps.
Despite the complexity, the shift toward blood-based testing represents a significant stride in Alzheimer’s diagnostics — one that may eventually make screening more accessible, affordable, and widely used at earlier stages of the disease.
Follow along here or on LinkedIn for more on-the-ground insights from AAIC 2025.
